Back

Splice site and de novo mutations can cause mixed gain of function/dominant negative PLCG2-associated immune dysregulation with cold urticaria (CU-PLAID)

Chou, S. R.; Bailey, A. C.; Baysac, K. C.; Oler, A.; Milner, J. D.; Ombrello, M. J.

2024-03-19 allergy and immunology
10.1101/2024.03.16.24304180
Show abstract

BackgroundPhospholipase C{gamma}2 (PLC{gamma}2) is an important signaling molecule that receives and transmits signals from various cell surface receptors in most hematopoietic lineages. Variants of PLCG2 cause PLC{gamma}2-associated immune dysregulation (PLAID), a family of conditions that are classified by mutational effect. PLAID with cold urticaria (CU-PLAID) is caused by in-frame deletions of PLCG2 that are dominant negative at physiologic temperatures but become spontaneously active at sub-physiologic temperatures. ObjectiveTo identify genetic lesions that cause PLAID by combining RNA sequencing of full-length PLCG2 with whole genome sequencing. MethodsWe studied nine probands with antibody deficiency and a positive evaporative cooling test, together with two known CU-PLAID patients and three healthy subjects. Illumina sequencing was performed on full-length PLCG2 cDNA synthesized from peripheral blood mononuclear cell RNA and whole genome sequencing was used to identify genetic lesions. Novel alternate transcripts were overexpressed in the Plcg2-deficient DT40 cell overexpression system. ERK phosphorylation was quantified by flow cytometry with and without BCR crosslinking. ResultsTwo probands expressed novel alternative transcripts of PLCG2 with in-frame deletions. The first, expressing PLCG2 without exons 18-19, carried a splice site mutation in intron 19. The second, expressing PLCG2 without exons 19-22, carried a 14kb de novo deletion of PLCG2. DT40 cells overexpressing the exon 18-19 or exon 19-22 deletions failed to phosphorylate ERK in response to BCR crosslinking. ConclusionIn addition to autosomal dominant genomic deletions, de novo deletions and splice site mutations of PLCG2 can also cause CU-PLAID. All of these can be identified by cDNA-based sequencing. Capsule SummaryBy identifying both the first de novo and splice site variants to cause PLCG2-associated immune dysregulation with cold urticaria (CU-PLAID), we demonstrate the diagnostic utility of PLCG2-specific RNA-sequencing.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
Journal of Experimental Medicine
based on 10 papers
Top 0.1%
8.5%
2
Nature Communications
based on 483 papers
Top 12%
6.6%
3
Journal of Clinical Immunology
based on 11 papers
Top 0.1%
5.5%
4
The Journal of Immunology
based on 19 papers
Top 0.1%
5.5%
5
Allergy
based on 13 papers
Top 0.5%
4.6%
6
Journal of Clinical Investigation
based on 50 papers
Top 0.6%
3.0%
7
Nature Immunology
based on 14 papers
Top 0.4%
2.9%
8
Clinical Immunology
based on 12 papers
Top 0.3%
2.9%
9
JCI Insight
based on 63 papers
Top 2%
2.9%
10
Communications Biology
based on 36 papers
Top 0.5%
2.6%
11
Blood
based on 14 papers
Top 0.5%
2.5%
12
The American Journal of Human Genetics
based on 77 papers
Top 4%
2.5%
50% of probability mass above
13
Science Immunology
based on 15 papers
Top 0.4%
2.5%
14
PLOS ONE
based on 1737 papers
Top 84%
2.4%
15
Clinical Infectious Diseases
based on 219 papers
Top 11%
2.4%
16
iScience
based on 74 papers
Top 2%
2.4%
17
Science Translational Medicine
based on 40 papers
Top 2%
2.4%
18
Cell
based on 28 papers
Top 0.9%
2.4%
19
Cell Genomics
based on 34 papers
Top 1%
2.4%
20
Cell Reports Medicine
based on 49 papers
Top 2%
2.4%
21
Frontiers in Immunology
based on 140 papers
Top 4%
1.9%
22
Journal of Allergy and Clinical Immunology
based on 15 papers
Top 0.8%
1.8%
23
Annals of the Rheumatic Diseases
based on 23 papers
Top 0.9%
1.4%
24
eLife
based on 262 papers
Top 21%
1.4%
25
Immunity
based on 11 papers
Top 0.6%
1.4%
26
mSphere
based on 27 papers
Top 1%
1.4%
27
Life Science Alliance
based on 11 papers
Top 0.3%
0.8%
28
Clinical Chemistry
based on 14 papers
Top 2%
0.8%
29
Journal of Medical Virology
based on 95 papers
Top 9%
0.8%
30
EBioMedicine
based on 21 papers
Top 2%
0.7%